Search
Displaying 201–210 of 779 for “retinitis clinical trial”
-
Foundation News
The four-year study will inform clinical trial design for emerging USH3 therapies.
-
Beacon Stories
18-year-old Marty Dubecky has a very unique decision to make. There are currently four gene therapy clinical trials for him to choose from to enroll in, which would have been unheard of 15 years ago when he was first diagnosed with XLRP.
-
Researchers Identify Regions in the Retina to Target Therapies for Certain RP Patients
Research NewsUniversity of Pennsylvania investigators studied retinas of patients and canines with retinitis pigmentosa caused by mild mutations in RHO
-
Biogen Entering into Licensing Agreement with Mass Eye and Ear to Develop PRPF31 Gene Therapy
Research NewsThe goal of the partnership is to advance a PRPF31 gene therapy into a clinical trial
-
French Gene Therapy Company Advancing Three Programs for Retinal Diseases
Research NewsHorama’s gene therapies are injections of healthy copies of a gene underneath the retina to compensate for the defective gene.
-
VISIONS 2024, the global conference of the Foundation Fighting Blindness, provides an excellent opportunity to connect with others from the blind and low vision community and learn about the latest research advancements, products and services for members of our community.
-
VISIONS 2024, the global conference (June 20–21, 2024) of the Foundation Fighting Blindness, provides an excellent opportunity to connect with others from the blind and low vision community and learn about the latest research advancements, products and services for members of our community.
-
Research News
Small data sets present challenges for developing rare disease AI tools
-
Choroideremia Gene Therapy Improves Vision in Human Study
Research NewsResearchers were able to improve vision in five of six people with choroideremia participating in a clinical trial.
-
FFB-CRI Launching Natural History Study for People with USH2A Mutations
Research NewsThe study — known as RUSH2A (“R” stands for “rate of progression”) — is beginning in spring 2017 and will take place at about 20 clinical sites around the world. RUSH2A investigators will use a variety of technologies to monitor changes in vision and retinal structure to document and analyze disease progression.
